Press Release November 17, 2020

InterVenn Biosciences Raises $34 Million To Commercialize Glycoproteomic LDT For Ovarian Cancer And Immuno-Oncology

The Life Sciences team advised InterVenn Biosciences on its $34 million Series B fundraising. The latest round was led by Anzu Partners with full participation of Genoa Ventures, Amplify Partners, and True Ventures; Xeraya Capital and the Ojjeh Family joined the syndicate as well.

InterVenn utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.

Funds will be used to commercialize the company’s High-Throughput-Glycoproteomic powered diagnostic for ovarian cancer; to service increasing partnership platform demand; and to accelerate development efforts for the immuno-oncology treatment response and colorectal cancer indications.

The Goodwin team was led by Maggie Wong and Kingsley Taft, and included Wynn Stateman, Jace Lynch, Tricia Hojo, and Ruowen Li.

For more details, read the press release and articles in VentureBeat, Crunchbase, and GenomeWeb.